These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23250739)

  • 1. Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of ΔEGFR/EGFRvIII.
    Gururaj AE; Gibson L; Panchabhai S; Bai M; Manyam G; Lu Y; Latha K; Rojas ML; Hwang Y; Liang S; Bogler O
    J Biol Chem; 2013 Feb; 288(5):3428-38. PubMed ID: 23250739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
    Latha K; Li M; Chumbalkar V; Gururaj A; Hwang Y; Dakeng S; Sawaya R; Aldape K; Cavenee WK; Bogler O; Furnari FB
    Int J Cancer; 2013 Feb; 132(3):509-20. PubMed ID: 22729867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
    Garnett J; Chumbalkar V; Vaillant B; Gururaj AE; Hill KS; Latha K; Yao J; Priebe W; Colman H; Elferink LA; Bogler O
    Neoplasia; 2013 Jan; 15(1):73-84. PubMed ID: 23359207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forced dimerization increases the activity of ΔEGFR/EGFRvIII and enhances its oncogenicity.
    Hwang Y; Chumbalkar V; Latha K; Bogler O
    Mol Cancer Res; 2011 Sep; 9(9):1199-208. PubMed ID: 21775422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.
    Mukasa A; Wykosky J; Ligon KL; Chin L; Cavenee WK; Furnari F
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2616-21. PubMed ID: 20133782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.
    Bonavia R; Inda MM; Vandenberg S; Cheng SY; Nagane M; Hadwiger P; Tan P; Sah DW; Cavenee WK; Furnari FB
    Oncogene; 2012 Sep; 31(36):4054-66. PubMed ID: 22139077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation.
    Perini G; Diolaiti D; Porro A; Della Valle G
    Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12117-22. PubMed ID: 16093321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
    Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
    J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells.
    Huang A; Ho CS; Ponzielli R; Barsyte-Lovejoy D; Bouffet E; Picard D; Hawkins CE; Penn LZ
    Cancer Res; 2005 Jul; 65(13):5607-19. PubMed ID: 15994933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.
    Sabò A; Kress TR; Pelizzola M; de Pretis S; Gorski MM; Tesi A; Morelli MJ; Bora P; Doni M; Verrecchia A; Tonelli C; Fagà G; Bianchi V; Ronchi A; Low D; Müller H; Guccione E; Campaner S; Amati B
    Nature; 2014 Jul; 511(7510):488-492. PubMed ID: 25043028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth.
    Lustig LC; Dingar D; Tu WB; Lourenco C; Kalkat M; Inamoto I; Ponzielli R; Chan WCW; Shin JA; Penn LZ
    Oncogene; 2017 Dec; 36(49):6830-6837. PubMed ID: 28806396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells.
    Jaganathan S; Yue P; Paladino DC; Bogdanovic J; Huo Q; Turkson J
    PLoS One; 2011 May; 6(5):e19605. PubMed ID: 21573184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
    Murphy DM; Buckley PG; Bryan K; Das S; Alcock L; Foley NH; Prenter S; Bray I; Watters KM; Higgins D; Stallings RL
    PLoS One; 2009 Dec; 4(12):e8154. PubMed ID: 19997598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
    Inda MM; Bonavia R; Mukasa A; Narita Y; Sah DW; Vandenberg S; Brennan C; Johns TG; Bachoo R; Hadwiger P; Tan P; Depinho RA; Cavenee W; Furnari F
    Genes Dev; 2010 Aug; 24(16):1731-45. PubMed ID: 20713517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
    Choe C; Chen N; Sawadogo M
    Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menin enhances c-Myc-mediated transcription to promote cancer progression.
    Wu G; Yuan M; Shen S; Ma X; Fang J; Zhu L; Sun L; Liu Z; He X; Huang D; Li T; Li C; Wu J; Hu X; Li Z; Song L; Qu K; Zhang H; Gao P
    Nat Commun; 2017 May; 8():15278. PubMed ID: 28474697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR.
    Chumbalkar V; Latha K; Hwang Y; Maywald R; Hawley L; Sawaya R; Diao L; Baggerly K; Cavenee WK; Furnari FB; Bogler O
    J Proteome Res; 2011 Mar; 10(3):1343-52. PubMed ID: 21214269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation.
    Stojanova A; Tu WB; Ponzielli R; Kotlyar M; Chan PK; Boutros PC; Khosravi F; Jurisica I; Raught B; Penn LZ
    Cell Cycle; 2016 Jul; 15(13):1693-705. PubMed ID: 27267444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC phosphorylation at novel regulatory regions suppresses transforming activity.
    Wasylishen AR; Chan-Seng-Yue M; Bros C; Dingar D; Tu WB; Kalkat M; Chan PK; Mullen PJ; Huang L; Meyer N; Raught B; Boutros PC; Penn LZ
    Cancer Res; 2013 Nov; 73(21):6504-15. PubMed ID: 24030976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.
    Lo HW; Cao X; Zhu H; Ali-Osman F
    Mol Cancer Res; 2010 Feb; 8(2):232-45. PubMed ID: 20145033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.